Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for multiple sclerosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiplesclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology To develop recommendations for disease-modifying therapy (DMT) for multiplesclerosis (MS).A multidisciplinary panel developed DMT recommendations, integrating findings from a systematic review; followed an Institute of Medicine-compliant process to ensure transparency
A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiplesclerosis: a systematic review and network meta-analysis This study is aimed at providing a quantitative evaluation on different therapies of spasticity caused by multiple sclerosis.PubMed and Embase database.We searched for randomized controlled trials that met the requirements. Percentages of improved patients' spasticity scale, mild adverse effect and severe adverse effect were extracted (...) in spasticity scale. Cannabinoids, tizanidine and diazepam had significantly more mild adverse effect reports than placebo. Surface under the cumulative ranking curves suggested that cannabinoids, botulinum toxin and transcutaneous electric nerve stimulation were preferable therapies.We recommended botulinum toxin as the optimal intervention for multiplesclerosis-related spasticity. Cannabinoids and transcutaneous electric nerve stimulation could also be considered as multiplesclerosis-related spasticity
Preapproval and postapproval evidence on drugs for multiplesclerosis To review the evidence supporting the European Union marketing authorization of drugs for multiplesclerosis (MS) and assess how far postmarketing research addresses information gaps at the time of approval.Through its database, we identified drugs approved by the European Medicines Agency and gathered data on pivotal trials from the European Public Assessment Reports and corresponding publications. We searched Medline
Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with MultipleSclerosis 1 Practice guideline: Disease-modifying therapies for adults with multiplesclerosis Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Alexander Rae-Grant, MD 1 ; Gregory S. Day, MD, MSc 2 ; Ruth Ann Marrie, MD, PhD 3 ; Alejandro Rabinstein, MD 4 ; Bruce A.C. Cree, MD, PhD, MAS 5 ; Gary S. Gronseth, MD 6 ; Michael Haboubi (...) of MultipleSclerosis Centers, Hackensack, NJ 9. Department of Neuroscience, St. Luke’s University Health Network, Bethlehem, PA 10. Department of Neurology, School of Medicine, University of Virginia, Charlottesville 11. Consortium of MultipleSclerosis Centers, Hackensack, NJ, and Department of Neurology, School of Medicine, Wayne State University, Detroit, MI 12. Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles 13. Neurology Department, Southern
Randomised controlled trial of a self-guided online fatigue intervention in multiplesclerosis Fatigue is a major disabling symptom in many chronic diseases including multiplesclerosis (MS), but treatment options are limited.Here, we tested the effectiveness of a self-guided , interactive, online fatigue management programme (ELEVIDA) based on principles of cognitive behavioural therapy (CBT) and related psychotherapeutic approaches (eg, mindfulness) for reducing fatigue in MS.Patients with MS
Chronic Cerebro-Spinal Venous Insufficiency in MultipleSclerosis: Is It the End? 29629362 2018 11 14 2288-7970 34 1 2018 Mar Vascular specialist international Vasc Specialist Int Chronic Cerebro-Spinal Venous Insufficiency in MultipleSclerosis: Is It the End? 16-18 10.5758/vsi.2018.34.1.16 Rasman Alessandro A Department of Political and Social Sciences, University of Trieste, Trieste, Italy. eng Journal Article 2018 03 31 Korea (South) Vasc Specialist Int 101633116 2288-7970 Conflict
[Effects of nutritional status on the multiplesclerosis disease: systematic review]. To review the available scientific literature about the effects of nutritional status on the multiplesclerosis disease.A systematic review of the scientific literature in the Medline (PubMed), Scopus, Cochrane Library and Web of Science databases through November 2016. Search equation: ("MultipleSclerosis"[Mesh] OR "MultipleSclerosis"[Title/Abstract] OR "Disseminated Sclerosis"[Title/Abstract] OR "Multiple (...) recovered, after applying inclusion and exclusion criteria, 29 articles were selected for review. Concordance between evaluators was 100.00%. The most studies established vitamin D levels. Others focused their research on finding out which nutrient deficits might be related to the multiplesclerosis development.Vitamin D may influence multiplesclerosis improvement. Sunlight and physical activity would be important factors, with nutritional status, in the course of this disease. It is necessary
Multiplesclerosis. Multiplesclerosis continues to be a challenging and disabling condition but there is now greater understanding of the underlying genetic and environmental factors that drive the condition, including low vitamin D levels, cigarette smoking, and obesity. Early and accurate diagnosis is crucial and is supported by diagnostic criteria, incorporating imaging and spinal fluid abnormalities for those presenting with a clinically isolated syndrome. Importantly (...) , there is an extensive therapeutic armamentarium, both oral and by infusion, for those with the relapsing remitting form of the disease. Careful consideration is required when choosing the correct treatment, balancing the side-effect profile with efficacy and escalating as clinically appropriate. This move towards more personalised medicine is supported by a clinical guideline published in 2018. Finally, a comprehensive management programme is strongly recommended for all patients with multiplesclerosis, enhancing
Siponimod versus placebo in secondary progressive multiplesclerosis (EXPAND): a double-blind, randomised, phase 3 study. No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiplesclerosis (SPMS). We assessed the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor1,5 modulator, on disability progression in patients with SPMS.This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 (...) hospital clinics and specialised multiplesclerosis centres in 31 countries. Using interactive response technology to assign numbers linked to treatment arms, patients (age 18-60 years) with SPMS and an Expanded Disability Status Scale score of 3·0-6·5 were randomly assigned (2:1) to once daily oral siponimod 2 mg or placebo for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression (CDP) events. The primary endpoint was time to 3-month CDP. Efficacy
2018LancetControlled trial quality: predicted high
Exploring cued and non-cued motor imagery interventions in people with multiplesclerosis: a randomised feasibility trial and reliability study Motor imagery (MI) is increasingly used in neurorehabilitation to facilitate motor performance. Our previous study results demonstrated significantly improved walking after rhythmic-cued MI in people with multiplesclerosis (pwMS). The present feasibility study was aimed to obtain preliminary information of changes in walking, fatigue, quality of life (...) ). Descriptive statistics were reported for all outcomes. Primary outcomes were walking speed (Timed 25-Foot Walk) and walking distance (6-Minute Walk Test). Secondary outcomes were recruitment rate, retention, adherence, acceptability, adverse events, MI ability (Kinaesthetic and Visual Imagery Questionnaire, Time-Dependent MI test), fatigue (Modified Fatigue Impact Scale) and QoL (MultipleSclerosis Impact Scale-29). The reliability of a gait analysis system used to assess gait synchronisation with music
EMA urgently reviewing multiplesclerosis medicine Zinbryta following cases of inflammatory brain disorders EMA urgently reviewing multiplesclerosis medicine Zinbryta following cases of inflammatory brain disorders | European Medicines Agency Search Search Menu EMA urgently reviewing multiplesclerosis medicine Zinbryta following cases of inflammatory brain disorders Press release 02/03/2018 Medicine to be voluntarily withdrawn from the market by the company The European Medicines Agency (EMA (...) ) has started an urgent review of the multiplesclerosis medicine Zinbryta (daclizumab) following 7 cases of serious inflammatory brain disorders in Germany, including encephalitis and meningoencephalitis, and one case in Spain. In parallel to the start of the review, the company that markets Zinbryta (Biogen Idec Ltd) has informed EMA of its intention to voluntarily withdraw the medicine's . Doctors in the EU will be contacted directly in the coming days with further information. Until then EMA
EMA recommends immediate suspension and recall of multiplesclerosis medicine Zinbryta EMA recommends immediate suspension and recall of multiplesclerosis medicine Zinbryta | European Medicines Agency Search Search Menu EMA recommends immediate suspension and recall of multiplesclerosis medicine Zinbryta Press release 07/03/2018 Evidence indicates risk of serious inflammatory brain disorders The European Medicines Agency (EMA) has recommended the immediate suspension and recall (...) of the multiplesclerosis medicine Zinbryta (daclizumab beta) following 12 reports of serious inflammatory brain disorders worldwide, including encephalitis and meningoencephalitis. Three of the cases were fatal. A preliminary review of the available evidence indicates that immune reactions observed in the reported cases may be linked to the use of Zinbryta. Zinbryta may also be linked to severe immune reactions affecting several other organs. To protect patients' health, EMA is recommending the immediate
The ability of clinical balance measures to identify falls risk in multiplesclerosis: a systematic review and meta-analysis To determine the ability of clinical measures of balance to distinguish fallers from non-fallers and to determine their predictive validity in identifying those at risk of falls.AMED, CINAHL, Medline, Scopus, PubMed Central and Google Scholar. First search: July 2015. Final search: October 2017.Inclusion criteria were studies of adults with a definite multiplesclerosis (...) is commonly not reported. Of those reported, the Activities-specific Balance Confidence Scale had the highest area under the receiver operating characteristic curve value (0.92), but without reporting corresponding measures of clinical utility.Clinical measures of balance differ significantly between fallers and non-fallers but have poor predictive ability for falls risk in people with multiplesclerosis.
Randomized Controlled Trial to Examine the Impact of Aquatic Exercise Training on Functional Capacity, Balance, and Perceptions of Fatigue in Female Patients With MultipleSclerosis To assess the effects of an 8-week aquatic exercise training program on functional capacity, balance, and perceptions of fatigue in women with multiplesclerosis (MS).Randomized controlled design.Referral center of an MS society.Women (N=32; mean age ± SD, 36.4±8.2y) with diagnosed relapsing-remitting MS. After
Evidenced-Based Cognitive Rehabilitation for Persons With MultipleSclerosis: An Updated Review of the Literature From 2007 to 2016 To update the clinical recommendations for cognitive rehabilitation of people with multiplesclerosis (MS), based on a systematic review of the literature from 2007 through 2016.Searches of MEDLINE, PsycINFO, and CINAHL were conducted with a combination of the following terms: attention, awareness, cognition, cognitive, communication, executive, executive function
Efficacy of Balance and Eye-Movement Exercises for Persons With MultipleSclerosis (BEEMS) To determine whether a multifaceted vestibular-related rehabilitation program (Balance and Eye-Movement Exercises for Persons with MultipleSclerosis; BEEMS) improves balance in persons with MS and whether there are differences in outcomes based on brainstem/cerebellar lesion involvement.A 2-arm, examiner-blinded, stratified (involvement vs no involvement of brainstem/cerebellar structures), randomized (...) , p < 0.0001), SF-36 Mental (3.9, 0.70-7.16, p = 0.02), and SF-36 Physical (3.2, 0.79-5.62, p = 0.01) scores. From baseline to 6 weeks, BEEMS participants with brainstem/cerebellar lesion involvement experienced greater improvements compared to those without in CDP-SOT composite (5.26, 0.34-10.2, p = 0.04) and MFIS total (-7.6, -14.0 to -1.33, p = 0.02) scores.BEEMS improved multiple outcomes regardless of whether brainstem/cerebellar lesions were present, supporting the generalizability of BEEMS
Fampridine (Fampyra) in cases of multiplesclerosis (MS) Fampridine (Fampyra®) in cases of multiplesclerosis (MS) | Report | National Health Care Institute You are here: Fampridine (Fampyra®) in cases of multiplesclerosis (MS) Search within English part of National Health Care Institute Search Fampridine (Fampyra®) in cases of multiplesclerosis (MS) Zorginstituut Nederland carried out an assessment of the medicinal product fampridine (Fampyra®). Based on the outcomes of the assessment